References
- Orton S Syphilis and blood donors: what we know, what we do not know, and what we need to know. Transfus Med Rev 2001;15:282–291. Epub 2001/ 10/23. 4 https://doi.org/10.1053/tm.2001.26956
- Yomtovian R, Palavecino E Bacterial contamination of blood components - History and epidemiology. In: Brecher ME, editor. Bacterial and parasitic contamination of blood components. 1 ed. Bethesda (MD): AABB Press; 2003. p. 1–30.
- Novak M Preservation of stored blood with sulfanilamide. JAMA 1939;113:3.
- Braine HG, Kickler TS, Charache P, Ness PM, Davis J, Reichart C, Fuller AK Bacterial sepsis secondary to platelet transfusion: an adverse effect of extended storage at room temperature. Transfusion 1986;26:391–393. Epub 1986/ 07/01. 4 https://doi.org/10.1046/j.1537-2995.1986.26486262752.x
- Schrezenmeier H, Walther-Wenke G, TH M, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007;47:644–652. Epub 2007/ 03/27. 4 https://doi.org/10.1111/j.1537-2995.2007.01166.x
- Kleinman S, Reed W, Stassinopoulos A A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013;53:1603–1618. Epub 2012/ 10/17. 7 https://doi.org/10.1111/j.1537-2995.2012.03928.x
- Lozano M, Cid J, Prowse C, McCullough J, Klein HG, Aubuchon JP Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature. Transfusion 2015;55:690. 3 https://doi.org/10.1111/trf.12996
- Groves JA, Foster GA, Dodd RY, Stramer SL West Nile virus activity in United States blood donors and optimizing detection strategies: 2014-2018. Transfusion 2020;60:94–105. Epub 2019/ 12/13. 1 https://doi.org/10.1111/trf.15620
- Mundt JM, Rouse L, Van den Bossche J, Goodrich RP Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014;90:957–964. Epub 2014/ 07/22. 5 https://doi.org/10.1111/php.12311
- Knobler R History of extracorporeal photopheresis. In: Greinix HT, Knobler R, editors. Extracorporeal photopheresis. 1 ed. Leipzig: De Gruyter; 2012. p. 2–6.
- Lozano M, Cid J Pathogen inactivation: coming of age. Curr Opin Hematol 2013;20:540–545. Epub 2013/ 10/10. 6 https://doi.org/10.1097/MOH.0b013e328365a18f
- Cid J Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review. Vox Sang 2017;112:607–613. 7 https://doi.org/10.1111/vox.12558
- Keil SD, Saakadze N, Bowen R, Newman JL, Karatela S, Gordy P, Marschner S, Roback J, Hillyer CD Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products. Transfusion 2015;55:858–863. Epub 2014/ 12/03. 4 https://doi.org/10.1111/trf.12945
- Schlenke P, Hagenah W, Irsch J, Sundin D, Corash L, Lin L, Kirchner H, Wagner T Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients. Ann Hematol 2011;90:1457–1465. Epub 2011/ 04/20. 12 https://doi.org/10.1007/s00277-011-1222-3
- Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, Muncunill J, Serret C, Serra N, Sedeno M Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 2014;54:158–168. Epub 2013/ 05/10. 1 https://doi.org/10.1111/trf.12232
- Snyder EL, Stramer SL, Benjamin RJ The safety of the blood supply–time to raise the bar. N Engl J Med 2015;372:1882–1885 Epub 2015/ 04/23. 20 https://doi.org/10.1056/NEJMp1500154
- Jimenez-Marco T, Garcia-Recio M, Girona-Llobera E Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient care. Transfusion 2018;58:1881–1889. Epub 2018/ 08/23. 8 https://doi.org/10.1111/trf.14797
- Lozano M, Cid J Analysis of reasons for not implementing pathogen inactivation for platelet concentrates. Transfus Clin Biol 2013;20:158–164. Epub 2013/ 04/17. 2 https://doi.org/10.1016/j.tracli.2013.02.017
- van der Meer PF, Ypma PF, van Geloven N, van Hilten JA, van Wordragen-Vlaswinkel RJ, Eissen O, Zwaginga JJ, Trus M, Beckers EAM, Te Boekhorst P, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood 2018;132:223–231. Epub 2018/ 05/19. 2 https://doi.org/10.1182/blood-2018-02-831289
- Garban F, Guyard A, Labussiere H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, et al. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: a Randomized Clinical Trial. JAMA Oncol 2018;4:468–475. Epub 2018/ 02/03. 4 https://doi.org/10.1001/jamaoncol.2017.5123
- Rebulla P, Vaglio S, Beccaria F, Bonfichi M, Carella A, Chiurazzi F, Coluzzi S, Cortelezzi A, Gandini G, Girelli G, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion 2017;57:1171–1183. Epub 2017/ 02/27. 5 https://doi.org/10.1111/trf.14042
- Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011;153:393–401. Epub 2011/ 03/23. 3 https://doi.org/10.1111/j.1365-2141.2011.08635.x
- Kerkhoffs J-LH, van Putten WLJ, Novotny VMJ, Te Boekhorst PAW, Schipperus MR, Zwaginga JJ, van Pampus LCM, de Greef GE, Luten M, Huijgens PC, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010;150:209–217. Epub 2010/ 05/29. 2 https://doi.org/10.1111/j.1365-2141.2010.08227.x
- Cazenave J-P, Folléa G, Bardiaux L, Boiron J-M, Lafeuillade B, Debost M, Lioure B, Harousseau J-L, Tabrizi R, Cahn J-Y Mirasol Clinical Evaluation Study G. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362–2375. Epub 2010/ 05/25. 11 https://doi.org/10.1111/j.1537-2995.2010.02694.x
- Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443–1452. Epub 2005/ 09/01. 9 https://doi.org/10.1111/j.1537-2995.2005.00550.x
- McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534–1541. Epub 2004/ 05/13. 5 https://doi.org/10.1182/blood-2003-12-4443
- van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426–2433. Epub 2002/ 11/29. 6 https://doi.org/10.1182/blood-2002-03-0932
- Brixner V, Bug G, Pohler P, Kramer D, Metzner B, Voss A, Casper J, Ritter U, Klein S, Alakel N, et al. Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial. Haematologica 2021;106:1086–1096. Epub 2021/ 02/05. 4 https://doi.org/10.3324/haematol.2020.260430
- Rebulla P, Garban F, van der Meer PF, Heddle NM, McCullough J A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets. Transfusion 2020;60:1267–1277. Epub 2020/ 04/24. 6 https://doi.org/10.1111/trf.15791
- Heddle NM, Cardoso M, van der Meer PF Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion. Transfusion 2020;60:1604–1611. Epub 2020/ 05/08. 7 https://doi.org/10.1111/trf.15779
- Prowse CV Component pathogen inactivation: a critical review. Vox Sang 2013;104:183–199. Epub 2012/ 11/09. 3 https://doi.org/10.1111/j.1423-0410.2012.01662.x
- Jimenez-Marco T, Garcia-Recio M, Girona-Llobera E Use and safety of riboflavin and UV light-treated platelet transfusions in children over a five-year period: focusing on neonates. Transfusion 2019;59:3580–3588. Epub 2019/ 10/07. 12 https://doi.org/10.1111/trf.15538
- Stolla M Pathogen reduction and HLA alloimmunization: more questions than answers. Transfusion 2019;59:1152–1155. Epub 2019/ 02/26. 3 https://doi.org/10.1111/trf.15211
- Chi X, Zhi L, Vostal JG Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model. Transfusion 2014;54:74–85. Epub 2013/ 05/10. 1 https://doi.org/10.1111/trf.12242
- Mowla SJ, Kracalik IT, Sapiano MRP, O’Hearn L, Andrzejewski C, Basavaraju SV A comparison of transfusion-related adverse reactions among apheresis platelets, whole blood-derived platelets, and platelets subjected to pathogen reduction technology as reported to the National Healthcare Safety Network Hemovigilance Module. Transfus Med Rev 2021. 35 2 78–84 https://doi.org/10.1016/j.tmrv.2021.03.003
- Custer B, Agapova M, Martinez RH The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461–2473. Epub 2010/ 05/26. 11 https://doi.org/10.1111/j.1537-2995.2010.02704.x